Apixaban in children (Merali 2023)
Source:vignettes/articles/Merali_2023_apixaban.Rmd
Merali_2023_apixaban.Rmd
library(nlmixr2lib)
library(PKNCA)
#>
#> Attaching package: 'PKNCA'
#> The following object is masked from 'package:stats':
#>
#> filter
library(rxode2)
#> rxode2 5.1.8 using 2 threads (see ?getRxThreads)
#> no cache: create with `rxCreateCache()`
library(dplyr)
#>
#> Attaching package: 'dplyr'
#> The following objects are masked from 'package:stats':
#>
#> filter, lag
#> The following objects are masked from 'package:base':
#>
#> intersect, setdiff, setequal, union
library(ggplot2)The paper
Merali et al. (2023) report the phase I study NCT01707394 (CV185118), in which 49 children from birth to <18 years at risk of venous or arterial thrombosis received a single oral dose of apixaban (0.1 mg sprinkle capsule in the neonate; 0.4 mg/mL oral solution otherwise; 1.08 to 2.43 mg/m^2). A population PK model was fitted to these data pooled with eight adult phase I studies and a second paediatric phase I study (Table S2): 254 subjects and 5,220 concentrations.
The final model (Table 2 and the displayed equations of the Methods)
is two-compartment with first-order absorption and elimination. CL/F and
Vc/F scale with baseline body weight (power exponents 0.71 and 0.879,
reference 67.4 kg), CL/F carries a fixed CYP3A4 maturation function of
age taken from Bouillon-Pichault 2011, Q/F is a power function of age
(reference 25 years), ka is 142% higher between 9 months and 18 years,
relative bioavailability falls with dose above 2.5 mg, and the neonatal
capsule has a fixed relative bioavailability of 1.1. The paper also
reports a linear relationship between plasma anti-factor Xa activity and
apixaban concentration (Figure 4), which the model file carries as the
algebraic output antiFXa.
Population
From Table 1 (the 49 dosed paediatric subjects of CV185118; mean (SD)):
| Age group | n | Age | Weight (kg) | BSA (m^2) | Dose |
|---|---|---|---|---|---|
| Birth to 27 days | 1 | 9 days at enrolment, 15 days at dosing | 3.1 | 0.2 | 0.1 mg capsule |
| 28 days to <9 months | 11 | 126.9 (67.2) days | 4.9 (1.7) | 0.3 (0.1) | 1.08 mg/m^2 |
| 9 months to <2 years | 9 | 13.3 (4.2) months | 8.3 (2.4) | 0.4 (0.1) | 1.08 (n = 6) or 2.43 (n = 3) mg/m^2 |
| 2 to <6 years | 8 | 3.6 (1.2) years | 15.9 (4.7) | 0.7 (0.1) | 1.17 mg/m^2 |
| 6 to <12 years | 10 | 7.4 (1.2) years | 29.8 (11.1) | 1.0 (0.2) | 1.80 mg/m^2 |
| 12 to <18 years | 10 | 13.7 (1.4) years | 49.9 (17.1) | 1.5 (0.3) | 2.19 mg/m^2 |
57% were female, 86% White, 10% Black and 4% other race. One 6-to-<12-year-old who vomited within 45 minutes of dosing was excluded from the PK analysis (n = 48). The pooled adult studies enrolled healthy volunteers (mean ages 26.7 to 42.0 years, mean weights 63.1 to 95.6 kg) dosed 2.5 to 50 mg (Table S2).
Source trace
| Quantity | Source |
|---|---|
| Two-compartment, first-order absorption and elimination | Methods “Population PK analysis”; Results “PK results” |
| Covariate equations for ka, CL/F, Vc/F, Vp/F, Q/F, TVF1 and F1 | Methods, displayed equations |
| PED9M definition (1 for 9 months to <18 years, else 0) | Methods, text after the equations |
lka, lcl, lvc,
lq, lvp
|
Table 2, theta1 to theta5 |
lgamma (theta6), logitifdepot50
(theta7) |
Table 2 |
e_wt_vc (theta8), e_wt_cl (theta9),
e_age_q (theta10), e_ped9m_ka (theta11) |
Table 2 |
cyp3a4_hill (theta12), cyp3a4_t50
(theta13), cyp3a4_birth (theta15), all FIXED |
Table 2; maturation from Bouillon-Pichault 2011 (reference 10) |
fdepot_capsule (theta14, FIXED) |
Table 2; Methods text “equal to 1.1 for subjects receiving neonatal formulation” |
etalka, block etalcl / etalvc
/ etalvp / etalq
|
Table 2 random effects (variances and covariances) |
expSd |
Table 2 residual ‘Exponential’ sigma = 0.0844 (variance); SD = sqrt(0.0844) |
lslope_antiFXa |
Discussion: “overall slope estimate of 0.0155 IU/ng” |
lrbase_antiFXa |
Digitised from the regression line of Figure 4 (see below) |
Deterministic checks
These checks use typical values only (zeroRe()), so both
sides of every comparison share the same parameters and no cohort is
involved.
# One subject per row of `cov`; dose into depot at time 0 and observations of
# the central compartment at `obsTimes`.
mkEvents <- function(cov, amt, obsTimes) {
do.call(rbind, lapply(seq_len(nrow(cov)), function(i) {
covRow <- cov[i, , drop = FALSE]
dose <- data.frame(id = i, time = 0, amt = amt[i], evid = 1, cmt = "depot")
obs <- data.frame(
id = i, time = obsTimes, amt = 0, evid = 0, cmt = "central"
)
ev <- rbind(dose, obs)
cbind(ev, covRow[rep(1, nrow(ev)), , drop = FALSE], row.names = NULL)
}))
}Relative bioavailability and maturation
grid <- data.frame(
WT = 67.4,
AGE = c(0, 0.244, 25, 25, 25, 25),
DOSE_APIXABAN_MG = c(2.5, 2.5, 2.5, 50, 10, 2.5),
FORM_CAPSULE = c(0, 0, 0, 0, 0, 1)
)
gridSim <- rxode2::rxSolve(
modTyp, mkEvents(grid, amt = grid$DOSE_APIXABAN_MG, obsTimes = 1),
returnType = "data.frame"
)
#> ℹ omega/sigma items treated as zero: 'etalka', 'etalcl', 'etalvc', 'etalvp', 'etalq'
#> Warning: multi-subject simulation without without 'omega'
gridRes <- cbind(grid, gridSim[, c("fmat", "frel", "fform")])
knitr::kable(
gridRes |>
dplyr::rename(
"Weight (kg)" = WT, "Age (y)" = AGE, "Dose (mg)" = DOSE_APIXABAN_MG,
"Neonatal capsule" = FORM_CAPSULE, "Maturation fraction" = fmat,
"Dose F1" = frel, "Formulation F1" = fform
),
digits = 4
)| Weight (kg) | Age (y) | Dose (mg) | Neonatal capsule | Maturation fraction | Dose F1 | Formulation F1 |
|---|---|---|---|---|---|---|
| 67.4 | 0.000 | 2.5 | 0 | 0.0500 | 1.0000 | 1.0 |
| 67.4 | 0.244 | 2.5 | 0 | 0.5250 | 1.0000 | 1.0 |
| 67.4 | 25.000 | 2.5 | 0 | 0.9801 | 1.0000 | 1.0 |
| 67.4 | 25.000 | 50.0 | 0 | 0.9801 | 0.6142 | 1.0 |
| 67.4 | 25.000 | 10.0 | 0 | 0.9801 | 0.9245 | 1.0 |
| 67.4 | 25.000 | 2.5 | 1 | 0.9801 | 1.0000 | 1.1 |
# Exact identities of the printed equations:
# maturation fraction = FBIRTH (0.05) at birth and (1 + 0.05) / 2 at the
# age of half-maturation, 0.244 y;
# TVF1 = 1 at 2.5 mg and 1 - expit(-0.465) at the 50 mg maximum dose;
# F1 for the neonatal formulation = 1.1.
stopifnot(
abs(gridRes$fmat[1] - 0.05) < 1e-10,
abs(gridRes$fmat[2] - 0.525) < 1e-10,
abs(gridRes$frel[3] - 1) < 1e-10,
abs(gridRes$frel[4] - (1 - 1 / (1 + exp(0.465)))) < 1e-10,
abs(gridRes$fform[6] - 1.1) < 1e-10
)The maturation function is still below 1 in adults (0.980 at 25
years), so exp(lcl) = 4.7 L/h is the CL/F of a hypothetical
fully mature 67.4-kg subject; the typical 25-year-old 67.4-kg adult has
CL/F 4.6 L/h. At the paediatric doses (0.1 to about 3.2 mg) the dose
term is inert below 2.5 mg and reduces F1 by under 2% at the adolescent
mean dose of 3.22 mg.
Typical parameters by age group against Table 3
Table 3 gives the geometric means of the individual (post hoc) ka, CL/F and Vc/F by age group. The model’s typical values at each group’s mean age and weight (Table 1) should land near them. This is a structural check: the individual estimates carry random effects and the covariates vary within a group, so agreement is expected to tens of percent, not exactly, but a mis-transcribed exponent, reference weight or maturation constant moves the young groups by a factor of two or more.
groups <- tibble::tribble(
~group, ~AGE, ~WT, ~ka_pub, ~cl_pub, ~vc_pub,
"Birth to 27 days", 15 / 365.25, 3.1, 0.55, 0.10, 1.82,
"28 days to <9 months", 126.9 / 365.25, 4.9, 0.72, 0.35, 2.69,
"9 months to <2 years", 13.3 / 12, 8.3, 1.34, 0.76, 4.61,
"2 to <6 years", 3.6, 15.9, 1.03, 1.62, 8.97,
"6 to <12 years", 7.4, 29.8, 1.15, 2.69, 15.4,
"12 to <18 years", 13.7, 49.9, 1.14, 3.85, 23.6
)
groupCov <- groups |>
dplyr::transmute(
AGE, WT,
DOSE_APIXABAN_MG = 1,
FORM_CAPSULE = as.integer(group == "Birth to 27 days")
) |>
as.data.frame()
typSim <- rxode2::rxSolve(
modTyp, mkEvents(groupCov, amt = rep(1, nrow(groupCov)), obsTimes = 1),
returnType = "data.frame"
)
#> ℹ omega/sigma items treated as zero: 'etalka', 'etalcl', 'etalvc', 'etalvp', 'etalq'
#> Warning: multi-subject simulation without without 'omega'
typRes <- groups |>
dplyr::mutate(
ka_mod = typSim$ka, cl_mod = typSim$cl, vc_mod = typSim$vc,
ka_pct = 100 * (ka_mod / ka_pub - 1),
cl_pct = 100 * (cl_mod / cl_pub - 1),
vc_pct = 100 * (vc_mod / vc_pub - 1)
)
knitr::kable(
typRes |>
dplyr::select(group, ka_mod, ka_pub, cl_mod, cl_pub, cl_pct, vc_mod, vc_pub, vc_pct) |>
dplyr::rename(
"Age group" = group,
"ka typical (1/h)" = ka_mod, "ka Table 3" = ka_pub,
"CL/F typical (L/h)" = cl_mod, "CL/F Table 3" = cl_pub, "CL/F %" = cl_pct,
"Vc/F typical (L)" = vc_mod, "Vc/F Table 3" = vc_pub, "Vc/F %" = vc_pct
),
digits = 2,
caption = "Typical ka, CL/F and Vc/F at each age group's mean age and weight against the Table 3 geometric means of the individual estimates."
)| Age group | ka typical (1/h) | ka Table 3 | CL/F typical (L/h) | CL/F Table 3 | CL/F % | Vc/F typical (L) | Vc/F Table 3 | Vc/F % |
|---|---|---|---|---|---|---|---|---|
| Birth to 27 days | 0.50 | 0.55 | 0.12 | 0.10 | 19.48 | 2.09 | 1.82 | 14.81 |
| 28 days to <9 months | 0.50 | 0.72 | 0.43 | 0.35 | 24.06 | 3.12 | 2.69 | 16.17 |
| 9 months to <2 years | 1.21 | 1.34 | 0.84 | 0.76 | 10.36 | 4.97 | 4.61 | 7.73 |
| 2 to <6 years | 1.21 | 1.03 | 1.53 | 1.62 | -5.52 | 8.79 | 8.97 | -1.96 |
| 6 to <12 years | 1.21 | 1.15 | 2.49 | 2.69 | -7.29 | 15.28 | 15.40 | -0.81 |
| 12 to <18 years | 1.21 | 1.14 | 3.67 | 3.85 | -4.58 | 24.03 | 23.60 | 1.83 |
# Deterministic, but the published side is a geometric mean of individual
# estimates over a covariate range, not a typical value at the mean. Realised
# CL/F differences run from -7% to +24% and Vc/F from -2% to +16%. A wrong
# weight exponent, reference weight or maturation constant moves the youngest
# groups by 2- to 10-fold, so a 35% envelope still goes red for them.
stopifnot(
nrow(typRes) == 6L,
max(abs(typRes$cl_pct)) < 35,
max(abs(typRes$vc_pct)) < 35,
# ka is a step at 9 months: 0.502 below it, 0.502 * 2.42 above it.
all(abs(typRes$ka_mod[1:2] - 0.502) < 1e-8),
all(abs(typRes$ka_mod[3:6] - 0.502 * 2.42) < 1e-8)
)The Table 3 ka geometric mean of the 28-day-to-<9-month group (0.72 1/h) lies between the two typical values because its upper age bound sits at the 9-month step and the individual estimates carry 54% CV of IIV on ka.
Anti-factor Xa activity
The Discussion gives the slope (0.0155 IU/ng, i.e. IU/mL per ng/mL) but no intercept. The maintainers digitised the regression line drawn in Figure 4 (23 points along the line, axes calibrated from the tick marks) and fitted a straight line to them: slope 0.01549 IU/mL per ng/mL, which reproduces the printed slope and confirms the line is the reported regression, and intercept 0.074 IU/mL, which is used in the model.
pdCov <- data.frame(WT = 67.4, AGE = 25, DOSE_APIXABAN_MG = 2.5, FORM_CAPSULE = 0)
pdSim <- rxode2::rxSolve(
modTyp, mkEvents(pdCov, amt = 2.5, obsTimes = seq(0, 24, by = 0.5)),
returnType = "data.frame"
)
#> ℹ omega/sigma items treated as zero: 'etalka', 'etalcl', 'etalvc', 'etalvp', 'etalq'
fit <- stats::lm(antiFXa ~ Cc, data = pdSim)
stats::coef(fit)
#> (Intercept) Cc
#> 0.0740 0.0155
stopifnot(
abs(stats::coef(fit)[["Cc"]] - 0.0155) < 1e-10,
abs(stats::coef(fit)[["(Intercept)"]] - 0.074) < 1e-10
)Virtual paediatric cohort
One arm per age group, with the 9-month-to-<2-year group split by its two dose levels as in Table 3. Ages and weights are drawn independently from normal distributions with the Table 1 mean and SD of each group, truncated to the group’s age bounds and to a plausible weight range; the single neonate is represented by subjects at the neonate’s age (15 days) and weight (3.1 kg). Every subject in an arm receives the arm’s mean absolute dose: the per-group means printed in the Methods (0.1, 0.29, 0.71, 1.82 and 3.22 mg), and for the two 9-month-to-<2-year dose levels the dose per m^2 times the group’s mean BSA of 0.4 m^2 (0.43 and 0.97 mg).
rxode2::rxSetSeed(20230403)
set.seed(20230403)
nPerArm <- 100L
arms <- tibble::tribble(
~arm, ~ageMean, ~ageSd, ~ageLo, ~ageHi, ~wtMean, ~wtSd, ~dose, ~capsule,
"Birth to 27 days", 15 / 365.25, 0, 15 / 365.25, 15 / 365.25, 3.1, 0, 0.1, 1L,
"28 days to <9 months", 126.9 / 365.25, 67.2 / 365.25, 28 / 365.25, 0.749, 4.9, 1.7, 0.29, 0L,
"9 months to <2 years (1.08 mg/m2)", 13.3 / 12, 4.2 / 12, 0.75, 1.999, 8.3, 2.4, 1.08 * 0.4, 0L,
"9 months to <2 years (2.43 mg/m2)", 13.3 / 12, 4.2 / 12, 0.75, 1.999, 8.3, 2.4, 2.43 * 0.4, 0L,
"2 to <6 years", 3.6, 1.2, 2, 5.999, 15.9, 4.7, 0.71, 0L,
"6 to <12 years", 7.4, 1.2, 6, 11.999, 29.8, 11.1, 1.82, 0L,
"12 to <18 years", 13.7, 1.4, 12, 17.999, 49.9, 17.1, 3.22, 0L
)
cohort <- do.call(rbind, lapply(seq_len(nrow(arms)), function(i) {
a <- arms[i, ]
data.frame(
arm = a$arm,
AGE = pmin(pmax(rnorm(nPerArm, a$ageMean, a$ageSd), a$ageLo), a$ageHi),
WT = pmin(pmax(rnorm(nPerArm, a$wtMean, a$wtSd), 0.5 * a$wtMean), 2 * a$wtMean),
DOSE_APIXABAN_MG = a$dose,
FORM_CAPSULE = a$capsule
)
}))
cohort$id <- seq_len(nrow(cohort))
stopifnot(nrow(cohort) == nrow(arms) * nPerArm, max(table(cohort$arm)) <= 200)
obsTimes <- c(0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72)
events <- mkEvents(
cohort[, c("AGE", "WT", "DOSE_APIXABAN_MG", "FORM_CAPSULE")],
amt = cohort$DOSE_APIXABAN_MG, obsTimes = obsTimes
)
sim <- rxode2::rxSolve(mod, events, returnType = "data.frame") |>
dplyr::mutate(id = as.integer(as.character(id))) |>
dplyr::left_join(cohort[, c("id", "arm")], by = "id")
stopifnot(nrow(sim) == nrow(cohort) * length(obsTimes), all(is.finite(sim$Cc)))
# Replicates the layout of Figure 2 (concentration-time by age group, semilog).
ggplot(dplyr::filter(sim, time > 0, time <= 26), aes(time, Cc, group = id)) +
geom_line(alpha = 0.1) +
stat_summary(aes(group = arm), fun = median, geom = "line", colour = "firebrick") +
facet_wrap(~arm, ncol = 2) +
scale_y_log10() +
labs(
x = "Time after dose (h)", y = "Apixaban concentration (ng/mL)",
title = "Simulated single-dose apixaban profiles by age group",
subtitle = "Grey: individual subjects; red: median. Compare Figure 2 of Merali 2023."
) +
theme_bw()
# Replicates Figure 3: individual CL/F versus age, with the Table 3 geometric
# means at each group's mean age for comparison.
indiv <- sim |>
dplyr::filter(time == 1) |>
dplyr::select(id, arm, AGE, cl)
ggplot(indiv, aes(AGE, cl)) +
geom_point(alpha = 0.3) +
geom_point(
data = groups, aes(AGE, cl_pub), colour = "firebrick", size = 3, shape = 17
) +
scale_y_log10() +
labs(
x = "Age (years)", y = "CL/F (L/h)",
title = "Individual CL/F versus age",
subtitle = "Black: simulated subjects; red: Table 3 geometric means. Compare Figure 3."
) +
theme_bw()
PKNCA validation
concData <- sim |>
dplyr::filter(!is.na(Cc)) |>
dplyr::select(id, time, Cc, arm)
stopifnot(sum(concData$time == 0) == nrow(cohort))
doseData <- cohort |>
dplyr::transmute(id, time = 0, amt = DOSE_APIXABAN_MG, arm)
concObj <- PKNCA::PKNCAconc(concData, Cc ~ time | arm + id, concu = "ng/mL", timeu = "h")
doseObj <- PKNCA::PKNCAdose(doseData, amt ~ time | arm + id, route = "extravascular", doseu = "mg")
intervals <- data.frame(start = 0, end = Inf, cmax = TRUE, tmax = TRUE, aucinf.obs = TRUE)
ncaRes <- PKNCA::pk.nca(PKNCA::PKNCAdata(concObj, doseObj, intervals = intervals))Comparison against Table 3
Table 3 reports geometric means of the post hoc Cmax and AUCinf and
the median Tmax per age group. ncaComparisonTable()
summarises the simulated subjects by their median, which for these
log-normally distributed exposures estimates the same quantity as a
geometric mean.
published <- tibble::tribble(
~arm, ~cmax, ~tmax, ~aucinf.obs,
"Birth to 27 days", 45.9, 4.54, 1120,
"28 days to <9 months", 64, 2.32, 806,
"9 months to <2 years (1.08 mg/m2)", 59.1, 1.60, 501,
"9 months to <2 years (2.43 mg/m2)", 148, 1.67, 1260,
"2 to <6 years", 49.9, 1.91, 423,
"6 to <12 years", 80, 1.71, 662,
"12 to <18 years", 96.5, 1.95, 815
)
cmp <- nlmixr2lib::ncaComparisonTable(
simulated = ncaRes,
reference = published,
by = "arm",
units = c(cmax = "ng/mL", tmax = "h", aucinf.obs = "ng*h/mL"),
tolerance_pct = 30
)
knitr::kable(
cmp,
caption = "Simulated (median) vs. Table 3 (geometric mean; Tmax median). * differs by more than 30%."
)| NCA parameter | arm | Reference | Simulated | % diff |
|---|---|---|---|---|
| Cmax (ng/mL) | Birth to 27 days | 45.9 | 38.5 | -16.1% |
| Cmax (ng/mL) | 28 days to <9 months | 64 | 55.3 | -13.6% |
| Cmax (ng/mL) | 9 months to <2 years (1.08 mg/m2) | 59.1 | 59.3 | +0.4% |
| Cmax (ng/mL) | 9 months to <2 years (2.43 mg/m2) | 148 | 134 | -9.7% |
| Cmax (ng/mL) | 2 to <6 years | 49.9 | 54.7 | +9.7% |
| Cmax (ng/mL) | 6 to <12 years | 80 | 83.4 | +4.2% |
| Cmax (ng/mL) | 12 to <18 years | 96.5 | 95.3 | -1.3% |
| Tmax (h) | Birth to 27 days | 4.54 | 5 | +10.1% |
| Tmax (h) | 28 days to <9 months | 2.32 | 4 | +72.4%* |
| Tmax (h) | 9 months to <2 years (1.08 mg/m2) | 1.6 | 1.5 | -6.3% |
| Tmax (h) | 9 months to <2 years (2.43 mg/m2) | 1.67 | 2 | +19.8% |
| Tmax (h) | 2 to <6 years | 1.91 | 1.5 | -21.5% |
| Tmax (h) | 6 to <12 years | 1.71 | 2 | +17.0% |
| Tmax (h) | 12 to <18 years | 1.95 | 2 | +2.6% |
| AUC0-∞ (obs) (ng*h/mL) | Birth to 27 days | 1120 | 834 | -25.5% |
| AUC0-∞ (obs) (ng*h/mL) | 28 days to <9 months | 806 | 652 | -19.1% |
| AUC0-∞ (obs) (ng*h/mL) | 9 months to <2 years (1.08 mg/m2) | 501 | 493 | -1.6% |
| AUC0-∞ (obs) (ng*h/mL) | 9 months to <2 years (2.43 mg/m2) | 1260 | 1160 | -8.1% |
| AUC0-∞ (obs) (ng*h/mL) | 2 to <6 years | 423 | 497 | +17.4% |
| AUC0-∞ (obs) (ng*h/mL) | 6 to <12 years | 662 | 726 | +9.6% |
| AUC0-∞ (obs) (ng*h/mL) | 12 to <18 years | 815 | 899 | +10.3% |
simGm <- as.data.frame(ncaRes) |>
dplyr::filter(PPTESTCD %in% c("cmax", "aucinf.obs")) |>
dplyr::group_by(arm, PPTESTCD) |>
dplyr::summarise(sim = exp(mean(log(PPORRES))), .groups = "drop") |>
dplyr::left_join(
tidyr::pivot_longer(published, c(cmax, aucinf.obs), names_to = "PPTESTCD", values_to = "pub") |>
dplyr::select(arm, PPTESTCD, pub),
by = c("arm", "PPTESTCD")
) |>
dplyr::mutate(pct = 100 * (sim / pub - 1))
simGm
#> # A tibble: 14 × 5
#> arm PPTESTCD sim pub pct
#> <chr> <chr> <dbl> <dbl> <dbl>
#> 1 12 to <18 years aucinf.obs 864. 815 6.07
#> 2 12 to <18 years cmax 91.0 96.5 -5.65
#> 3 2 to <6 years aucinf.obs 491. 423 16.0
#> 4 2 to <6 years cmax 56.6 49.9 13.5
#> 5 28 days to <9 months aucinf.obs 662. 806 -17.9
#> 6 28 days to <9 months cmax 55.1 64 -13.9
#> 7 6 to <12 years aucinf.obs 723. 662 9.19
#> 8 6 to <12 years cmax 81.3 80 1.67
#> 9 9 months to <2 years (1.08 mg/m2) aucinf.obs 489. 501 -2.40
#> 10 9 months to <2 years (1.08 mg/m2) cmax 58.2 59.1 -1.52
#> 11 9 months to <2 years (2.43 mg/m2) aucinf.obs 1152. 1260 -8.59
#> 12 9 months to <2 years (2.43 mg/m2) cmax 135. 148 -8.90
#> 13 Birth to 27 days aucinf.obs 790. 1120 -29.5
#> 14 Birth to 27 days cmax 37.8 45.9 -17.7
# Cohort-derived geometric means against geometric means of 1 to 11 real
# subjects per group, with ages, weights and doses only matched in their
# group means. Realised: median -5%, 75th percentile of the absolute
# difference 16%, largest -30% (the neonate AUC, discussed below). The centre
# of the seven-arm comparison is gated tightly and the envelope loosely: a
# mis-transcribed clearance, weight exponent, maturation constant or unit
# shifts every arm (or all the young arms) by tens of percent to several-fold.
stopifnot(
nrow(simGm) == 14L,
all(is.finite(simGm$pct)),
abs(stats::median(simGm$pct)) < 20,
stats::quantile(abs(simGm$pct), 0.75) < 35
)Tmax is read off the simulation grid (1.5, 2, 2.5, 3, 4, 5 h), so its comparison is coarse. The 28-day-to-<9-month arm is the one starred row: below 9 months the typical ka is the adult 0.502 1/h, giving a simulated median Tmax of about 4 h against the paper’s 2.32 h (range 1.46 to 9.42 h), and the Table 3 ka geometric mean for that group (0.72 1/h) indicates that the individual estimates sat above the typical value.
The paper does not compute AUCinf by NCA: it defines it as
Dose / (CL/F) with the individual post hoc CL/F. In the
youngest children the unscaled peripheral volume (18 L) and the very
small age-scaled Q/F produce a slow return phase that a 72-hour profile
cannot extrapolate, so the PKNCA AUCinf above underestimates the
neonate’s exposure. The paper’s own definition, evaluated with each
simulated subject’s CL/F and relative bioavailability, reads it
directly:
aucDef <- sim |>
dplyr::filter(time == 1) |>
dplyr::mutate(auc = 1000 * DOSE_APIXABAN_MG * frel * fform / cl) |>
dplyr::group_by(arm) |>
dplyr::summarise(auc_sim = exp(mean(log(auc))), .groups = "drop") |>
dplyr::left_join(published[, c("arm", "aucinf.obs")], by = "arm") |>
dplyr::mutate(pct = 100 * (auc_sim / aucinf.obs - 1))
knitr::kable(
aucDef |>
dplyr::rename(
"Arm" = arm, "Dose / (CL/F), simulated (ng*h/mL)" = auc_sim,
"Table 3 AUCinf (ng*h/mL)" = aucinf.obs, "% diff" = pct
),
digits = 1,
caption = "Geometric mean of Dose * F1 / (CL/F) per arm against Table 3 AUCinf."
)| Arm | Dose / (CL/F), simulated (ng*h/mL) | Table 3 AUCinf (ng*h/mL) | % diff |
|---|---|---|---|
| 12 to <18 years | 863.7 | 815 | 6.0 |
| 2 to <6 years | 494.0 | 423 | 16.8 |
| 28 days to <9 months | 748.1 | 806 | -7.2 |
| 6 to <12 years | 723.2 | 662 | 9.2 |
| 9 months to <2 years (1.08 mg/m2) | 505.1 | 501 | 0.8 |
| 9 months to <2 years (2.43 mg/m2) | 1192.7 | 1260 | -5.3 |
| Birth to 27 days | 927.4 | 1120 | -17.2 |
Anti-factor Xa versus concentration (Figure 4)
ggplot(dplyr::filter(sim, time %in% c(0.5, 1, 2, 4, 6, 12, 24)), aes(Cc, antiFXa)) +
geom_point(aes(colour = arm), alpha = 0.3, size = 0.8) +
coord_cartesian(xlim = c(0, 200), ylim = c(0, 3.1)) +
labs(
x = "Apixaban concentration (ng/mL)", y = "Anti-FXa (IU/mL)", colour = NULL,
title = "Anti-factor Xa activity versus apixaban concentration",
subtitle = "Typical-value regression evaluated at simulated concentrations. Compare Figure 4."
) +
theme_bw() +
theme(legend.position = "bottom", legend.text = element_text(size = 6))
Assumptions and deviations
-
Printed CL/F equation. In the published typesetting
of the CL/F equation the bracket of the maturation term encloses
1 - theta15 * Age^theta12, which taken literally makes the maturation fraction negative above about 37 years (the adults in the dataset). The model uses the standard form of the cited Bouillon-Pichault 2011 function,theta15 + (1 - theta15) * Age^theta12 / (Age^theta12 + theta13^theta12), with theta15 named FBIRTH in Table 2. This form reproduces the Table 3 CL/F geometric means (see the typical-value check above). -
Anti-factor Xa intercept digitised. The paper
reports only the slope of the paediatric anti-FXa regression. The
intercept, 0.074 IU/mL, was digitised by the maintainers from the
regression line drawn in Figure 4; the slope digitised from the same
line (0.01549) reproduces the printed 0.0155. The linear mixed-effects
regression’s random effects and residual error are not reported, so
antiFXais a typical-value relationship with no error model. The assay was heparin-calibrated (STA Liquid Anti-Xa Heparin or Rotachrom), soantiFXais in IU/mL, not drug-equivalent ng/mL. - IIV covariance block. The printed variances and covariances of the CL/F, Vc/F, Vp/F and Q/F block reproduce the r^2 values in the Table 2 footnote, but at their printed precision the 4 x 4 block is very slightly indefinite (smallest eigenvalue -2.4e-5), so it cannot be sampled. The off-diagonal covariances are scaled by 0.99 (each correlation reduced by 1%); the variances are as printed.
-
Residual error. Table 2 reports a single
“Exponential” residual variance (0.0844, SD 0.29) and a negative minimum
objective function value (-5805.653), consistent with log-transformed
concentrations; the model uses
lnorm(expSd)withexpSd = sqrt(0.0844) = 0.2905. -
PED9M. Derived from
AGEinside the model (AGE >= 0.75andAGE < 18, with 9 months taken as 0.75 years), so no separate column is needed. Adults and infants under 9 months share the reference ka. -
Age and weight.
AGEis postnatal age in years; the paper does not use gestational or postmenstrual age.WTis baseline weight. The Q/F age effect makes Q/F very small in infants (0.08 L/h at 4 months), so the disposition is effectively one-compartment in the youngest children. - Virtual cohort. Ages and weights are drawn independently within each age group from the Table 1 means and SDs, and each arm receives the group’s mean absolute dose rather than a per-subject BSA-based dose (subject heights are not reported). Table 3 is built from individual post hoc estimates in 1 to 11 subjects per group, so the comparison is a centre-of-distribution check, not a reproduction of each group’s individuals.
- Not extracted. The adult phase I studies’ individual data and Figure S1 (VPC) are not reproduced; the paper’s push-pull sampling comparison is not a model.
- No erratum found. No correction notice for doi:10.1002/psp4.12935 was found on Europe PMC as of 2026-10-26.